The Trump administration and a coalition of physicians, public health experts, and advocates urged commercial insurers to streamline prior authorization, and major insurers like UnitedHealthcare, Cigna, Aetna, CVS Health, and Humana signed a six-part pledge to reduce these delays. The articles frame prior authorization as just one of many denial-of-care tools used by the industry, which collectively shape how patients access treatment. A core critique is the industry’s float, the cash insurers hold between collecting premiums and paying claims, which incentivizes delaying care to earn interest and fund investments. By stretching the time to reimburse and layering administrative barriers, insurers profit while patients experience treatment delays or denials. The pieces emphasize the broader, systemic use of denial tactics beyond prior authorization, highlighting the profit motive behind delayed medical care. The overarching message is a call for transparency and reform to curb the aggressive use of denial tools that harm patients and inflate insurer profits.